title: Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin.
abstract: OBJECTIVE
  The purpose of this study was to determine that the administration of an angiotensin converting enzyme (ACE) inhibitor enalapril would confer protection against doxorubicin-induced experimental heart failure, and attenuate the development of left ventricular dysfunction.
  
  
  METHODS
  Seventeen dogs were chronically instrumented with an intracoronary catheter and received doxorubicin weekly for 4 weeks. Animals were assigned to two groups: group 1: untreated heart failure; and group 2: simultaneous enalapril administration (5 mg twice a week). Hemodynamic data were obtained at week 0 and 12. Echocardiography was performed weekly.
  
  
  RESULTS
  Survival improved with simultaneous enalapril administration (36% in group 1 vs. 100% in group 2, P=0.04). The increase in the left ventricular end-diastolic pressure was significantly reduced at week 12 (17+/-1 mmHg in group 1 vs. 9+/-1 mmHg in group 2, P=0.0042). The fall in left ventricular stroke work index was significantly prevented (52% in group 1 vs. 21% in group 2, P=0.006). The increase in right ventricular end-diastolic diameter was significantly reduced by enalapril prophylaxis.
  
  
  CONCLUSIONS
  Simultaneous treatment with enalapril was beneficial in the prevention of doxorubicin-induced cardiomyopathy.
authors.affiliation: Division of Cardiovascular Surgery, Department of Surgery, Maimomides Medical Center, Administration Building, Rm D, Department of Surgery, 4802 10th Ave, Brooklyn, NY 11219, USA. mishavayn@aol.com
authors.forename: Mikhail
authors.initials: M
authors.lastname: Vaynblat
authors.forename: Himansu R
authors.initials: HR
authors.lastname: Shah
authors.forename: Dinesh
authors.initials: D
authors.lastname: Bhaskaran
authors.forename: Geeta
authors.initials: G
authors.lastname: Ramdev
authors.forename: Wellington J
authors.initials: WJ
authors.lastname: Davis
authors.forename: Joseph N
authors.initials: JN
authors.lastname: Cunningham
authors.forename: Mario
authors.initials: M
authors.lastname: Chiavarelli
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents; D001794:Blood Pressure / Q000187:drug effects; D004195:Disease Models, Animal; D004285:Dogs; D004317:Doxorubicin; D004656:Enalapril / Q000627:therapeutic use; D006333:Heart Failure / Q000139:chemically induced / Q000188:drug therapy; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D008955:Models, Cardiovascular; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced* / Q000188:drug therapy*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000970:Antineoplastic Agents; D004656:Enalapril; D004317:Doxorubicin